China Resources Pharma: Placing Coverage Under Review
We are placing coverage of narrow-moat-rated China Resources Pharmaceutical 03320 under review pending the transfer of coverage to a new analyst. We expect to revisit our coverage of this company over the next three months. Our most recent fair value estimate was HKD 6.40.
The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar’s editorial policies.